Cargando…
An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies
BACKGROUND: Over the last two decades, humanity has observed the extraordinary anomaly caused by novel, weird coronavirus strains, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). As the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus h...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366110/ https://www.ncbi.nlm.nih.gov/pubmed/34429257 http://dx.doi.org/10.1016/j.jiph.2021.08.014 |
_version_ | 1783738844074475520 |
---|---|
author | Farooqi, Tahmeena Malik, Jonaid Ahmad Mulla, Almas Hanif Al Hagbani, Turki Almansour, Khaled Ubaid, Mohammed Abrar Alghamdi, Saleh Anwar, Sirajudheen |
author_facet | Farooqi, Tahmeena Malik, Jonaid Ahmad Mulla, Almas Hanif Al Hagbani, Turki Almansour, Khaled Ubaid, Mohammed Abrar Alghamdi, Saleh Anwar, Sirajudheen |
author_sort | Farooqi, Tahmeena |
collection | PubMed |
description | BACKGROUND: Over the last two decades, humanity has observed the extraordinary anomaly caused by novel, weird coronavirus strains, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). As the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has made its entry into the world, it has dramatically affected life in every domain by continuously producing new variants. The vaccine development is an ongoing process, although some vaccines got marketed. The big challenge is now whether the vaccine candidates can provide long-lasting protection or prevention against mutant variants. METHODS: The information was gathered from various journals, electronic searches via Internet-based information such as PubMed, Google Scholar, Science Direct, online electronic journals, WHO landscape, world meters, WHO website, and News. RESULTS: This review will present and discuss some coronavirus disease 19 (COVID-19) related aspects including: the pathophysiology, epidemiology, mutant variants vaccine candidates, vaccine efficacy, and management strategies. Due to the high death rate, continuous spread, an inadequate workforce, lack of required therapeutics, and incomplete understanding of the viral strain, it becomes crucial to build the knowledge of its biological characteristics and make available the rapid diagnostic and vital therapeutic machinery for the combat and management of an infection. CONCLUSION: The data summarizes current research on the COVID 19 infection and therapeutic interventions, which will direct future decision-making on the effort-worthy phases of the COVID 19 and the development of critical therapeutics. The only possible solution is the vaccine development targeting against all variant strains to halt its progress; the identified theoretical and practical knowledge can eliminate the gaps to improve a better understanding of the novel coronavirus structure and its design of a vaccine. In addition, to that the long-lasting protection is another challenging objective that need to be looked into. |
format | Online Article Text |
id | pubmed-8366110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83661102021-08-16 An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies Farooqi, Tahmeena Malik, Jonaid Ahmad Mulla, Almas Hanif Al Hagbani, Turki Almansour, Khaled Ubaid, Mohammed Abrar Alghamdi, Saleh Anwar, Sirajudheen J Infect Public Health Review Article BACKGROUND: Over the last two decades, humanity has observed the extraordinary anomaly caused by novel, weird coronavirus strains, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). As the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has made its entry into the world, it has dramatically affected life in every domain by continuously producing new variants. The vaccine development is an ongoing process, although some vaccines got marketed. The big challenge is now whether the vaccine candidates can provide long-lasting protection or prevention against mutant variants. METHODS: The information was gathered from various journals, electronic searches via Internet-based information such as PubMed, Google Scholar, Science Direct, online electronic journals, WHO landscape, world meters, WHO website, and News. RESULTS: This review will present and discuss some coronavirus disease 19 (COVID-19) related aspects including: the pathophysiology, epidemiology, mutant variants vaccine candidates, vaccine efficacy, and management strategies. Due to the high death rate, continuous spread, an inadequate workforce, lack of required therapeutics, and incomplete understanding of the viral strain, it becomes crucial to build the knowledge of its biological characteristics and make available the rapid diagnostic and vital therapeutic machinery for the combat and management of an infection. CONCLUSION: The data summarizes current research on the COVID 19 infection and therapeutic interventions, which will direct future decision-making on the effort-worthy phases of the COVID 19 and the development of critical therapeutics. The only possible solution is the vaccine development targeting against all variant strains to halt its progress; the identified theoretical and practical knowledge can eliminate the gaps to improve a better understanding of the novel coronavirus structure and its design of a vaccine. In addition, to that the long-lasting protection is another challenging objective that need to be looked into. The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021-10 2021-08-16 /pmc/articles/PMC8366110/ /pubmed/34429257 http://dx.doi.org/10.1016/j.jiph.2021.08.014 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Article Farooqi, Tahmeena Malik, Jonaid Ahmad Mulla, Almas Hanif Al Hagbani, Turki Almansour, Khaled Ubaid, Mohammed Abrar Alghamdi, Saleh Anwar, Sirajudheen An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies |
title | An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies |
title_full | An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies |
title_fullStr | An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies |
title_full_unstemmed | An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies |
title_short | An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies |
title_sort | overview of sars-cov-2 epidemiology, mutant variants, vaccines, and management strategies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366110/ https://www.ncbi.nlm.nih.gov/pubmed/34429257 http://dx.doi.org/10.1016/j.jiph.2021.08.014 |
work_keys_str_mv | AT farooqitahmeena anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT malikjonaidahmad anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT mullaalmashanif anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT alhagbaniturki anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT almansourkhaled anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT ubaidmohammedabrar anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT alghamdisaleh anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT anwarsirajudheen anoverviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT farooqitahmeena overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT malikjonaidahmad overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT mullaalmashanif overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT alhagbaniturki overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT almansourkhaled overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT ubaidmohammedabrar overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT alghamdisaleh overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies AT anwarsirajudheen overviewofsarscov2epidemiologymutantvariantsvaccinesandmanagementstrategies |